Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics Plc. (ADAP)
:ADAP
ADAP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.26 - $1.65
Previous CloseN/A
Volume813.54K
Average Volume (3M)1.63M
Market Cap
$74.41M
Enterprise Value$131.49M
Total Cash (Recent Filing)$143.99M
Total Debt (Recent Filing)$25.23M
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 15, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding255,883,210
10 Day Avg. Volume2,871,902
30 Day Avg. Volume1,625,397
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.43
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.61
Enterprise Value/Ebitda-3.45
Forecast
1Y Price Target
$2.13Price Target Upside634.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune’s Earnings Call: TECELRA Success and Future Outlook
PremiumCompany Announcements
Adaptimmune’s Strategic Moves in Cancer Therapy
PremiumCompany Announcements
Adaptimmune Therapeutics Reports Q4 2024 Business Update
PremiumPre-Earnings
Is ADAP a Buy, Before Earnings?PremiumCompany Announcements
Adaptimmune Therapeutics Announces Key Leadership Changes
---
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsPositive topline data from lete-cel's pivotal IGNYTE-ESO study supports ADAP’s plans for a rolling BLA submission.
Product LaunchADAP reported first revenue of $1.2 million from the Tecelra launch, indicating solid progress.
Regulatory ApprovalTecelra's FDA approval has been well-received, with multiple inquiries from medical professionals, indicating strong market interest.
Bears Say
Financial StabilityThe company faces going concern issues and has hired a bank to explore strategic options.
R&D PipelineDiscontinuation of preclinical PRAME and CD70 pipeline programs raises concerns about the company's future R&D activities.
Sales PerformanceZero sales were reported for the Tecelra launch, and no meaningful revenue is expected shortly.
---
Ownership Overview
48.53% Insiders
0.10% Mutual Funds
0.01% Other Institutional Investors
51.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADAP FAQ
What was Adaptimmune Therapeutics Plc.’s price range in the past 12 months?
Adaptimmune Therapeutics Plc. lowest stock price was $0.26 and its highest was $1.65 in the past 12 months.
What is Adaptimmune Therapeutics Plc.’s market cap?
Adaptimmune Therapeutics Plc.’s market cap is $74.41M.
When is Adaptimmune Therapeutics Plc.’s upcoming earnings report date?
Adaptimmune Therapeutics Plc.’s upcoming earnings report date is May 15, 2025 which is in 52 days.
How were Adaptimmune Therapeutics Plc.’s earnings last quarter?
Adaptimmune Therapeutics Plc. released its earnings results on Mar 20, 2025. The company reported -$0.035 earnings per share for the quarter, missing the consensus estimate of -$0.03 by -$0.005.
Is Adaptimmune Therapeutics Plc. overvalued?
According to Wall Street analysts Adaptimmune Therapeutics Plc.’s price is currently Undervalued.
Does Adaptimmune Therapeutics Plc. pay dividends?
Adaptimmune Therapeutics Plc. does not currently pay dividends.
What is Adaptimmune Therapeutics Plc.’s EPS estimate?
Adaptimmune Therapeutics Plc.’s EPS estimate is -0.13.
How many shares outstanding does Adaptimmune Therapeutics Plc. have?
Adaptimmune Therapeutics Plc. has 255,883,210 shares outstanding.
What happened to Adaptimmune Therapeutics Plc.’s price movement after its last earnings report?
Adaptimmune Therapeutics Plc. reported an EPS of -$0.035 in its last earnings report, missing expectations of -$0.03. Following the earnings report the stock price went down -37.778%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics Plc.?
Currently, no hedge funds are holding shares in ADAP
---
Adaptimmune Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.13 (634.48% Upside)
$2.13 (634.48% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 37.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.35%
12-Months-Change
Fundamentals
Return on Equity
-53.54%
Trailing 12-Months
Asset Growth
7.01%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics Plc.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlights substantial progress in the TECELRA launch, strong manufacturing and reimbursement success, and promising developments for future products like Lete-cel. However, the company faces challenges in securing additional capital to reach profitability by 2027 and delayed financial reporting. Overall, the positive aspects, particularly in product launch and efficiency, outweigh the financial and capital concerns.Read More>---
ADAP Stock 12 Month Forecast
Average Price Target
$2.13
▲(634.48% Upside)
Technical Analysis
Gilead Sciences
―
Bluebird Bio
―
Fate Therapeutics
―
Iovance Biotherapeutics
―
Immatics
―
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
8/11 ratings generated profit
1 Year Average Return
+32.91%
reiterated a sell rating 4 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +32.91% per trade.
---